Science. 1985 Nov 29;230(4729):992. doi: 10.1126/science.230.4729.992-c.
In the letter by M. F. Balandrin and J. A. Klocke (13 Sept., p. 1036), it was incorrectly stated that nabilone (Cesamet) has been approved for marketing by the Food and Drug Administration. Nabilone has not yet been approved by the FDA. The synthetic cannabinoid recently approved is in fact dronabinol (Marinol), a synthetic form of delta-9-tetra-hydrocannabinol. In the same letter, the affiliation of the authors should have been Native Plants, Inc., not Nature Plants, Inc. In the original article by Balandrin et al. (7 June, p. 1154), references 23 and 65 were incorrect. They should have been as follows: 23. Y. Aharonowitz and G. Cohen, Sci. Am. 245, 140 (September 1981); 65. D. E. Eveleigh, Sci. Am. 245, 154 (September 1981).
在 M. F. 巴兰丁和 J. A. 克洛克的信（9 月 13 日，第 1036 页）中，错误地指出纳布隆（塞塞美特）已被食品和药物管理局批准上市。纳布隆尚未获得 FDA 的批准。最近批准的合成大麻素实际上是 dronabinol（Marinol），一种 delta-9-四氢大麻酚的合成形式。在同一封信中，作者的隶属关系应该是 Native Plants, Inc.，而不是 Nature Plants, Inc. 在巴兰丁等人的原始文章中（6 月 7 日，第 1154 页），参考文献 23 和 65 是不正确的。它们应该是：23. Y. Aharonowitz 和 G. Cohen, Sci. Am. 245, 140 (September 1981); 65. D. E. Eveleigh, Sci. Am. 245, 154 (September 1981).
